Insider Trading March 31, 2026

BioLife Solutions Chief Quality and Operations Sells 2,577 Shares in Planned Transaction

Karen A. Foster executed a Rule 10b5-1 sale worth $49,401 as the stock trades near its 52-week low amid mixed financial signals

By Hana Yamamoto BLFS
BioLife Solutions Chief Quality and Operations Sells 2,577 Shares in Planned Transaction
BLFS

Karen A. Foster, Chief Quality and Operations at BioLife Solutions Inc (NASDAQ: BLFS), sold 2,577 shares on March 23, 2026, under a Rule 10b5-1 trading plan. The transaction, executed at a weighted average price of $19.17, totaled $49,401 and leaves Foster with 108,758 shares held directly. The sale occurs while BLFS is trading close to its 52-week low and after the company posted fourth-quarter 2025 results that topped expectations on both earnings and revenue.

Key Points

  • Karen A. Foster sold 2,577 BioLife Solutions shares on March 23, 2026, for $49,401 at a weighted average price of $19.17; prices ranged from $18.99 to $19.35.
  • The sale was executed under a Rule 10b5-1 trading plan adopted on December 4, 2025; Foster retains 108,758 shares following the transaction.
  • BioLife reported Q4 2025 EPS of $0.22 and revenue of $24.8 million, both above analysts' expectations; the stock trades near its 52-week low and is down 22% year-to-date, with analysts holding $30-$34 price targets while InvestingPro flags current levels as appearing overvalued.

Karen A. Foster, who serves as Chief Quality and Operations at BioLife Solutions Inc (NASDAQ: BLFS), reported a sale of 2,577 shares of the company’s common stock on March 23, 2026, according to a Form 4 filing with the Securities and Exchange Commission.

The disposal was recorded at a weighted average price of $19.17 per share, producing total proceeds of $49,401. Transaction prices in the block ranged from $18.99 to $19.35. After the sale, Foster is listed as directly owning 108,758 shares of BioLife Solutions.

The filing notes the sale was carried out pursuant to a Rule 10b5-1 trading plan that Foster adopted on December 4, 2025. The use of a 10b5-1 arrangement is stated explicitly in the SEC filing.

The insider sale comes as BioLife’s stock trades roughly 7% above its 52-week low of $17.86, and the share price is down about 22% year-to-date. Market commentary included in the filing context cites InvestingPro analysis, which characterizes the stock as appearing overvalued at current levels, even as sell-side analysts continue to maintain price targets in the $30 to $34 range.

InvestingPro is referenced as offering 11 additional tips on BLFS, including notes on profitability expectations and valuation measures, along with a comprehensive Pro Research Report that covers the company’s key investment factors.


In separate corporate news disclosed alongside the transaction, BioLife Solutions reported fourth-quarter 2025 financial results that exceeded analysts’ expectations. The company posted earnings per share of $0.22 versus a consensus estimate of -$0.01, and reported revenue of $24.8 million compared with an expected $24.05 million.

Those quarterly figures are presented in the filing as evidence of the company beating market forecasts, with revenue and EPS both coming in above analysts’ projections for the period.

The combination of an insider sale executed under a prearranged trading plan, a stock trading near its yearly low and a quarter that outperformed expectations creates a mixed informational picture for investors and market watchers. The SEC Form 4 documents the mechanics and timing of Foster’s transactions, while the company’s reported results and third-party valuation commentary provide the surrounding financial context.

Risks

  • Interpretation of the insider sale is constrained by the fact that it was conducted under a Rule 10b5-1 trading plan adopted December 4, 2025 - the prearranged nature of the plan limits conclusions about current insider sentiment.
  • Valuation disagreement exists - InvestingPro’s view that BLFS appears overvalued at current levels contrasts with analyst price targets in the $30-$34 range, creating uncertainty for investors on fair value.
  • Share price volatility and downside risk are evident given BLFS is trading approximately 7% above its 52-week low of $17.86 and is down 22% year-to-date, which impacts equity investors and market confidence in the healthcare/biotech sector.

More from Insider Trading

Daxor CFO Acquires $9,900 in Stock as Company Posts Revenue Gain and Completes $8.1M Offering Mar 31, 2026 C3.ai Director Executes Offset Transactions as Analysts Trim Targets After Weak Quarter Mar 31, 2026 Universal Insurance Director Sells $68k in UVE Stock; Company Posts Strong EPS Beat in Q4 2025 Mar 31, 2026 UTI Legal Chief Disposes $888,115 in Shares as Company Posts Mixed Q1 Results Mar 31, 2026 Ligand Director Executes Option Exercise, Sells $433,842 in Stock as Shares Rally Mar 31, 2026